Combined Analysis of the Prevalence of Drug-Resistant Hepatitis B Virus in Antiviral Therapy-Experienced Patients in Europe (CAPRE).

  • HIV Clinical and Translational Research
January 01, 2016 By:
  • Hermans LE
  • Svicher V
  • Pas SD
  • Salpini R
  • Alvarez M
  • Ben Ari Z
  • Boland G
  • Bruzzone B
  • Coppola N
  • Seguin-Devaux C
  • Dyda T
  • Garcia F
  • Kaiser R
  • Kose S
  • Krarup H
  • Lazarevic I
  • Lunar MM
  • Maylin S
  • Micheli V
  • Mor O
  • Paraschiv S
  • Paraskevis D
  • Poljak M
  • Puchhammer-Stockl E
  • Simon F
  • Stanojevic M
  • Stene-Johansen K
  • Tihic N
  • Trimoulet P
  • Verheyen J
  • Vince A
  • Weis N
  • Yalcinkaya T
  • Lepej SZ
  • Perno C
  • Boucher CA
  • Wensing AM
  • Hepvir working group of the European Society for Translational Antiviral Research.

BACKGROUND: European guidelines recommend treatment of chronic hepatitis B virus infection (CHB) with the nucleos(t)ide analogs (NAs) entecavir or tenofovir. However, many European CHB patients have been exposed to other NAs, which are associated with therapy failure and resistance. The CAPRE study was performed to gain insight in prevalence and characteristics of NA resistance in Europe. METHODS: A survey was performed on genotypic resistance testing results acquired during routine monitoring of CHB patients with detectable serum hepatitis B virus DNA in European tertiary referral centers. RESULTS: Data from 1568 patients were included. The majority (73.8%) were exposed to lamivudine monotherapy. Drug-resistant strains were detected in 52.7%. The most frequently encountered primary mutation was M204V/I (48.7%), followed by A181T/V (3.8%) and N236T (2.6%). In patients exposed to entecavir (n = 102), full resistance was present in 35.3%. Independent risk factors for resistance were age, viral load, and lamivudine exposure (P < .001). CONCLUSIONS: These findings support resistance testing in cases of apparent NA therapy failure. This survey highlights the impact of exposure to lamivudine and adefovir on development of drug resistance and cross-resistance. Continued use of these NAs needs to be reconsidered at a pan-European level.

2016 Jan. J Infect Dis.213(1):39-48. Epub 2015 Jul 1.
Other information